Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a subset of head and neck cancer k | Cancer ...

An expert discusses how recent data on adjuvant anti–PD-1 trials highlight the significance of disease-free survival (DFS) ...

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

Foresight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...